Olea sublingual allergoid immunotherapy administered with two different treatment regimens

Allergy and Asthma Proceedings

Volumn 31, Issue 2, 2010, Pages

  Leonardi, Salvatore ^a   Arena, Antonio ^b   Bruno, Marco E ^c   Cannaò, Paola M ^d   D'Anneo, Roberto W ^e   Falagiani, Paolo ^c   Gammeri, Enrico ^b   Mistrello, Gianni ^c   Nicolini, Alessandra ^f   Ricciardi, Luisa ^g   Valenti, Giuseppe ^h   Longo, Rosaria ^a   Rosa, Mario La ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b ASL 5   (Italy)

^c Lofarma SpA   (Italy)

^d Allergology Ambulatory ^*  (Italy)

^e Papardo Hospital   (Italy)

^f OMPA Hospital   (Italy)

^g UNIVERSITY OF MESSINA   (Italy)

^h ASL 10   (Italy)

Author keywords

Allergen; Allergic rhinitis; Asthma; Carbamylated allergoid; Olea allergy; Sublingual coseasonal immunotherapy

Indexed keywords

CETIRIZINE; FLUTICASONE PROPIONATE; IMMUNOMODULATING AGENT; LAIS; LORATADINE; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; OLIVE TREE; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; STATISTICAL SIGNIFICANCE; SUBLINGUAL IMMUNOTHERAPY; TREATMENT DURATION; VISUAL ANALOG SCALE; WELLBEING;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANTIGENS, PLANT; ASTHMA; CHILD; CLINICAL PROTOCOLS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; MALE; OLEA; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, SEASONAL; SEASONS;

EID: 77950853694     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3316     Document Type: Article

References (17)

1. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351: 629-632, 1998. (Pubitemid 28098445)
2. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: Multicenter post-marketing surveillance study. Allergy 56:989-992, 2001. (Pubitemid 32835605)
3. Di Rienzo V, Pagani A, Parmiani S, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 54:1110-1113, 1999. (Pubitemid 29482012)
4. Rossi RE, and Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 18:277-285, 2005. (Pubitemid 40825890)
5. Passalacqua G, Lombardi C, Guerra L, et al. Sublingual immunotherapy: No more doubts. Eur Ann Allergy Clin Immunol 37:314-320, 2005.
6. Giordano T, Quarta C, Bruno ME, et al. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. Eur Ann Allergy Clin Immunol 9:310-312, 2006. (Pubitemid 46032847)
7. La Grutta S, Arena A, D'Anneo RW, et al. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial. Eur Ann Allergy Clin Immunol 39:40-44, 2007.
8. Agostinis F, Tellarini L, Canonica GW, et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 60:133, 2005.
9. D'Anneo RW, Arena A, Gammeri E, et al. Parietaria sublingual allergoid immunotherapy with a co-seasonal treatment schedule. Allergol Immunopathol 36:79-84, 2008.
10. Mistrello G, Brenna O, Roncarolo D, et al. Monomeric chemically modified allergens: Immunologic and physicochemical characterization. Allergy 51:8-15, 1996. (Pubitemid 26104694)
11. Bousquet PJ, Combescure C, Klossek JM, et al. Changes in visual analogue scale in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol 123:1349-1354, 2009.
12. Pfaar O, and Klimex L. for the study group. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: A double blind, placebo-controlled trial. Ann Allergy Asthma Immunol 100:256-263, 2008.
13. Gammeri E, Arena A, D'Anneo R, and La Grutta S. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 33:142-144, 2005. (Pubitemid 40896350)
14. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117:802-809, 2006.
15. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-γ- and interleukin-10- production. Clin Exp Allergy 36:261-272, 2006. (Pubitemid 43344707)
16. Calderon M, and Essendrop M. Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Invest Clin Immunol 16:338-344, 2006. (Pubitemid 44953951)
17. Di Gioacchino M, Perrone A, Petrarca C, et al. Early cytokine modulation after the rapid induction phase of sublingual immunotherapy with mite monomeric allergoids. Int J Immunopathol Pharmacol 21:969-976, 2008.